Fight against novel coronavirus pneumonia joint venture e-commerce providers launched online medical services

GBI was informed that novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was published by the National Health Protection Commission (referred to as the "trial plan") According to the previous "nucleic acid positive" standard, not all patients can be diagnosed In this regard, the trial scheme added "clinical diagnosis" to the case diagnosis classification of Hubei Province, corrected the previous diagnosis and screening results, so as to further improve the success rate of treatment In February 12th, novel coronavirus pneumonia was reported in 14840 cases in Hubei Province, 13332 of which were diagnosed clinically Novel coronavirus pneumonia is diagnosed by 20%~30%, the vice director of Beijing Chaoyang Hospital, Tong Zhaohui, vice president of the central steering group The diagnosis of the disease is only based on the etiology, and the rest depends on clinical diagnosis Isolation at home and less going out is one of the effective methods to control the epidemic situation, but for patients with chronic diseases who need regular follow-up, hospitals and other vulnerable areas may increase the possibility of infection A novel coronavirus epidemic prevention and control program was issued by the National Health Insurance Bureau, which has recently issued a notice on optimizing the medical care service to promote the prevention and control of new coronavirus infections It encourages the implementation of the "long prescription" reimbursement policy during the epidemic period, and supports the medical institutions to increase the dosage of the single prescription according to the actual situation of the patients, so as to reduce the number of patients to the medical institutions Patients with chronic diseases, such as diseases, are supported to relax the prescription dosage to 3 months after doctors' evaluation In order to ensure that patients with chronic diseases can reduce their going out and regulate their medication on time, multinational pharmaceutical companies began to launch online pharmaceutical services in combination with internet hospitals and e-commerce On February 12, in order to help patients with chronic diseases achieve one-stop medical convenience services such as online consultation, prescription, dispensing and access to cutting-edge diagnosis and treatment information, Boehringer Ingelheim, together with JD health, Ali health, micro medicine, expert doctors, Medical Union, Jianke and other local leading Internet hospitals and e-commerce, launched one-stop online medical services to solve the diagnosis and treatment difficulties and purchase drugs for patients with chronic diseases during the epidemic Difficult questions ·Online public consultation activities: bringer Ingelheim supports four Internet hospitals, namely micro medicine, expert doctor, Ali health and Jianke, to carry out online public consultation projects and free consultation for the public ·Online contactless drug purchase activity: bringer Ingelheim, together with Jingdong pharmacy and Ali health pharmacy, carried out "opportunities for chronic disease care" and "chronic disease welfare plan" respectively Patients can log in to the e-commerce platform to provide legal prescriptions to realize contactless drug purchase and drug delivery home service The activity covers 10 products in the four fields of chronic lung disease, cardiovascular disease, endocrine and central nervous system The health times launched online medical services in collaboration with pharmaceutical companies such as JD health and Novartis,